Loading
companiesCompany
Guardian Bio
Guardian Bio turns a patient's stem cells into dendritic cells, the immune system's teachers, trains them against that patient's tumour and gives them back to restart the immune attack.
Overview
Guardian Bio is developing a dendritic cell therapy platform: patient-derived stem cells are differentiated into therapeutic dendritic cells, loaded against multiple antigens from the patient's own tumour and reinfused to activate cytotoxic T cells and natural killer cells. The rationale is that dendritic cell dysfunction in cancer patients limits the effect of other immunotherapies. The company is preclinical with a very small team; no sourced financing rounds are recorded.
Headquarters
Boston, MA, US
Funding
All startupsStartupYC S22
Investors
Type
Stage
Startup · Y Combinator Summer 2022
Website
Similar pages
- CompanyTareBio
Shares Y Combinator, Off-the-shelf cancer vaccines and the tag yc.
- CompanyAdventris Pharmaceuticals
Shares Y Combinator, Off-the-shelf cancer vaccines and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.